http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006008045-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3b43cd7382a8b607a90da7f83e264e5c http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_17f6e89ee1b63afb2c0ca17433a71d34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bdeadd465e281d316314ea2c46bc60fe http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5d1596f64ec0b2dac5334b2cf05b88bb |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-172 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate | 2005-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b0a5b7f4850f6eb87023bd7f8e21e346 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_765faf2cca145fcf1573dc994d92eaf6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_79261ae3af4e210d3376b65eb3e76809 |
| publicationDate | 2006-01-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2006008045-A1 |
| titleOfInvention | Single nucleotide polymorphisms as prognostic tool to diagnose adverse drug reactions (adr) and drug efficacy |
| abstract | The invention provides diagnostic methods and kits including oligo and/or polynucleotides or derivatives, including as well antibodies determining whether a human subject is at risk of getting adverse drug reaction after statin therapy or whether the human subject is a high or low responder or a good a or bad metabolizer of statins. The invention provides further diagnostic methods and kits including antibodies determining whether a human subject is at risk for a cardiovascular disease. Still further the invention provides polymorphic sequences and other genes. The present invention further relates to isolated polynucleotides encoding a phenotype associated (PA) gene polypeptide useful in methods to identify therapeutic agents and useful for preparation of a medicament to treat cardiovascular disease or influence drug response, the polynucleotide is selected from the group comprising: SEQ ID 1-131 with allelic variation as indicated in the sequences section contained in a functional surrounding like full length cDNA for PA gene polypeptide and with or without the PA gene promoter sequence. Sequences: The sequence section contains all phenotype associated (‘PA’) SNPs and adjacent genomic sequences. The position of the polymorphisms that were used for the association studies (‘baySNP’) is indicated. Sometimes additional variations are found in the surrounding genomic sequence, that are marked by it’s respective IUPAC code. Although those surrounding SNPs were not explicitly analyzed, they likely exihibit a similar association to a phenotype as the baySNP (due to linkage disequillibrium, Reich D.E. et al. Nature 411, 199-204, 2001). |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9092391-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10519502-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2014140387-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015066485-A3 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2010522537-A |
| priorityDate | 2004-07-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 784.